Screener
Kymera Therapeutics KYMR Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | $119,481 | $78,388 | $217,644 | $158,643 |
| General and administrative | 21,126 | 17,645 | 41,484 | 33,916 |
| Total operating expenses | 140,607 | 96,033 | 259,128 | 192,559 |
| Loss from operations | (75,607) | (84,557) | (159,763) | (158,983) |
| Other income (expense): | ||||
| Interest and other income | 14,477 | 8,051 | 29,459 | 16,968 |
| Interest and other expense | (81) | (108) | (141) | (180) |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's other operating expenses?
- Kymera Therapeutics (KYMR) reported other operating expenses of $140.61M in Q2 2026.
- How has Kymera Therapeutics's other operating expenses changed year-over-year?
- Kymera Therapeutics's other operating expenses increased by 46.4% year-over-year, from $96.03M to $140.61M.
- What is the long-term trend for Kymera Therapeutics's other operating expenses?
- Over 4 years (2021 to 2025), Kymera Therapeutics's other operating expenses has grown at a 22.4% compound annual growth rate (CAGR), from $173.36M to $388.61M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Kymera Therapeutics's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude